Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer (Study Group of Immunochemotherapy with PSK for Gastric Cancer) (1994)

Peer-Reviewed Study · Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J · May 7, 1994

Nakazato H et al., 1994-05-07: Randomised trial at 46 Japanese institutions in 262 patients after curative gastrectomy: adding PSK to mitomycin plus fluorouracil improved 5-year disease-free rate (70.7% vs 59.4%) and 5-year survival (73.0% vs 60.0%).

PSK improved both the 5-year disease-free rate (70.7 vs 59.4% in standard treatment group, p = 0.047) and 5-year survival (73.0 vs 60.0%, p = 0.044).

Abstract

Nakazato H et al., 1994-05-07: Randomised trial at 46 Japanese institutions in 262 patients after curative gastrectomy: adding PSK to mitomycin plus fluorouracil improved 5-year disease-free rate (70.7% vs 59.4%) and 5-year survival (73.0% vs 60.0%). Minimum follow-up 5 years. PSK supplied by Kureha; funding statement not carried in the PubMed record. Comparator: standard adjuvant chemotherapy alone (no placebo described). A published comment followed (Lancet 1994;344:274). Study type: randomized trial.